

Press Release

JUBILANT RECEIVES USFDA APPROVALS FOR 4 DOSAGE FORMULATIONS IN CVS AND CNS THERAPEUTIC AREAS

Noida (UP), India, September 20, 2012

Jubilant Life Sciences Ltd, an integrated Pharmaceutical and Life Sciences Company having global presence, announced today that one of its US subsidiaries, Jubilant Cadista Pharmaceuticals Inc. has received approvals from the U.S. Food and Drug Administration (US FDA) for:

- Escitalopram Tablets USP, 5mg, 10mg and 20mg
- Olanzapine Orally Disintegrating Tablet 5mg, 10mg, 15 mg and 20mg
- Losartan Potassium Tablets USP, 25 mg, 50mg and 100 mg
- Losartan Potassium and Hydrochlorothiazide Tablets USP, 50 mg/12.5 mg, 100 mg/12.5 mg and 100 mg/25 mg

Commenting on the approval, Mr Shyam S Bhartia, Chairman & Managing Director and Mr Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences said, “The recent USFDA approvals for four oral solid dosage formulations reinforce our growth strategy through new product launches and further demonstrate our strength in vertical integration from in-house APIs to Generics for cost competitive advantage.”

Escitalopram is used for acute treatment of generalized anxiety disorder and acute & maintenance treatment of major depressive disorders with its branded version, LEXAPRO® enjoying a market size of about US\$ 2.7 Billion. Further, Jubilant’s dossier and ANDA applications for this drug are pending for approval in EU and a few ROW countries.

Olanzapine ODT is a bioequivalent generic version of ZYPREXA ZYDIS® Orally Disintegrating Tablets indicated for the treatment of schizophrenia and for the short term treatment of acute manic or mixed episodes associated with Bipolar I disorder. Annual US sales of the generic version are more than US\$ 350 Million. It has already been commercially launched in Europe and some other Emerging Markets by Jubilant.

Losartan Potassium is a potent, highly specific angiotensin receptor blocker (ARB). It is desirable for an effective treatment of hypertension and also lowers the chance of stroke in patients with high blood pressure and heart problem called left ventricular hypertrophy. It can also be used to slow the worsening of diabetic kidney disease (nephropathy) in patients with type 2 diabetes who have/had high blood pressure. Annual sales of the branded version, COZAAR® are approximately US\$ 940 Million.



Jubilant Life Sciences Ltd.
1A, Sector 16A, Noida – 201301, India
Tel.: +91 120 4361000
www.jubl.com

Losartan Potassium and Hydrochlorothiazide Tablets is a combination of ARB and a diuretic. Annual sales for the branded drug HYZAAR® is approximately US\$ 670 Million. Jubilant has already launched generic versions of both in Europe and the two filings are awaiting approval in few other markets.

Escitalopram and Olanzapine ODT would be manufactured in Jubilant's dosage formulations facility at Roorkee, India. Losartan Potassium and its variant would be manufactured at the facility in Maryland, USA.

LEXAPRO® is trademark of Forest Laboratories, Inc; ZYPREXA ZYDIS® of Eli Lilly & Co; COZAAR® and HYZAAR® of Merck & Co., Inc.

About Jubilant Life Sciences Limited

Jubilant Life Sciences Limited is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Generics, Specialty Pharmaceuticals and Life Science Ingredients. It also provides Services in Contract Manufacturing and Drug Discovery and Development. The Company's strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of ~6300 multicultural people across the globe, the Company is committed to deliver value to its customers spread across 90 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com.

For more information please contact:

For Investors

Nidhi Aggarwal

Jubilant Life Sciences Limited, Ph: +91-120 4361002

E-mail: nidhi_aggarwal@jubl.com

Siddharth Rangnekar

Citigate Dewe Rogerson, Ph: +91-22 6645 1209

E-mail: siddharth@cdr-india.com

For Media

Sudhakar Safaya

Jubilant Life Sciences Limited, Ph: +91-120 4361034

E-mail: sudhakar_safaya@jubl.com

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.